Aion Therapeutic (XCNQ:AION) EBIT: C$-6.31 Mil (TTM As of Jan. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aion Therapeutic EBIT?

Aion Therapeutic XCNQ:AION EBIT is C$-6.31 Mil as of Jan. 2025.

Aion Therapeutic's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2025 was C$-0.13 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2025 was C$-6.31 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aion Therapeutic's annualized ROC % for the quarter that ended in Jan. 2025 was -29.04%. Aion Therapeutic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2025 was -518.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aion Therapeutic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2025 was -119.57%.

Aion Therapeutic  (XCNQ:AION) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aion Therapeutic's annualized ROC % for the quarter that ended in Jan. 2025 is calculated as:

ROC % (Q: Jan. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2024 ) + Invested Capital (Q: Jan. 2025 ))/ count )
=-0.960204 * ( 1 - -0% )/( (3.289423 + 3.322574)/ 2 )
=-0.960204/3.3059985
=-29.04 %

where

Invested Capital(Q: Oct. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.54164 - 2.475641 - ( 0.093695 - max(0, 5.648569 - 1.425145+0.093695))
=3.289423

Invested Capital(Q: Jan. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.20638 - 2.642576 - ( 0.01382 - max(0, 5.879066 - 1.120296+0.01382))
=3.322574

Note: The Operating Income data used here is four times the quarterly (Jan. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Aion Therapeutic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jan. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2024  Q: Jan. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.525056/( ( (0.116495 + max(-1.970337, 0)) + (0.086084 + max(-1.987274, 0)) )/ 2 )
=-0.525056/( ( 0.116495 + 0.086084 )/ 2 )
=-0.525056/0.1012895
=-518.37 %

where Working Capital is:

Working Capital(Q: Oct. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.109937 + 0.582978 + 0.580776) - (2.475641 + 0 + 0.768387)
=-1.970337

Working Capital(Q: Jan. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.136716 + 0.407532 + 0.538193) - (2.642576 + 0 + 0.427139)
=-1.987274

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aion Therapeutic's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jan. 2025 )
=-6.314242/5.281
=-119.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aion Therapeutic EBIT Related Terms

Aion Therapeutic EBIT Historical Data

* Premium members only.

The historical data trend for Aion Therapeutic's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aion Therapeutic EBIT Chart

Aion Therapeutic Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
EBIT
Get a 7-Day Free Trial -0.35 -8.08 -3.74 -0.11 -6.12

Aion Therapeutic Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -5.35 -0.32 -0.52 -0.13

XCNQ:AION vs CBDY, GRPS, PLSH: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aion Therapeutic EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's EV-to-EBIT falls into.


Aion Therapeutic EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of C$-6.31 Mil mean?
Aion Therapeutic (XCNQ:AION) has a EBIT of C$-6.31 Mil as of Jan. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aion Therapeutic.
Is Aion Therapeutic's EBIT too high?
Aion Therapeutic's current EBIT is C$-6.31 Mil.
How does Aion Therapeutic's EBIT compare to CBDY and GRPS?
Aion Therapeutic's EBIT of C$-6.31 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aion Therapeutic. Aion Therapeutic's current EBIT is C$-6.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aion Therapeutic stock overvalued right now?
Aion Therapeutic (XCNQ:AION) has a current EBIT of C$-6.31 Mil. The current EBIT is C$-6.31 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Aion Therapeutic (XCNQ:AION), the current EBIT is C$-6.31 Mil as of Jan. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aion Therapeutic Business Description

Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.